Hyperglycemia supports ineffective inflammation by neutrophils during staphylococcal infectionJOURNAL OF IMMUNOLOGYIF3.42025-11-010PRE
Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological AgeANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52015-08-0110OAAI
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese SubjectsCLINICAL THERAPEUTICSIF3.62015-07-0124PREAI
Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 InhibitorCLINICAL THERAPEUTICSIF3.62015-03-0141PREAI
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover studyDIABETES OBESITY & METABOLISMIF5.72015-01-0575OAAI
PHARMACODYNAMIC (PD) DIFFERENCES BETWEEN CANAGLIFLOZIN (CANA) 300 MG AND DAPAGLIFLOZIN (DAPA) 10 MG FOR URINARY GLUCOSE EXCRETION (UGE), RENAL THRESHOLD FOR GLUCOSE (RTG), AND POSTPRANDIAL PLASMA GLUCOSE (PPG) EXCURSION IN HEALTHY PARTICIPANTSDIABETES RESEARCH AND CLINICAL PRACTICEIF7.42014-11-010PREAI
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trialMETABOLISM-CLINICAL AND EXPERIMENTALIF11.92014-10-0143OAAI
CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study2型糖尿病患者的CCR2拮抗作用: 一项随机,安慰剂对照研究DIABETES OBESITY & METABOLISMIF5.72014-05-2533PREAI
Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy ParticipantsCLINICAL THERAPEUTICSIF3.62014-05-0144OAAI
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion Results of a randomized, placebo-controlled studyDIABETES CAREIF16.62013-07-11219OAAI
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetesDIABETES OBESITY & METABOLISMIF5.72012-03-1490PREAI
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of JNJ-38431055, a Novel GPR119 Receptor Agonist and Potential Antidiabetes Agent, in Healthy Male SubjectsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52011-10-0541PREAI
Influence of Continuous Venovenous Hemofiltration and Continuous Venovenous Hemodiafiltration on the Disposition of DoripenemANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52011-03-0116OAAI
Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy menANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52008-10-0134OAAI